Sermorelin

Origin and Structure

Sermorelin is a synthetic 29-amino-acid peptide corresponding to residues 1-29 of endogenous human growth hormone releasing hormone (GHRH). It is the shortest fragment of GHRH that retains full biological activity at the GHRH receptor — the native hormone is 44 residues long, but the N-terminal 29 residues carry the receptor-binding signal. The compound was developed by Lawrence A. Frohman and colleagues in the early 1980s and brought to market by Serono as Geref.

The FDA approved Geref in December 1997 for the treatment of idiopathic growth hormone deficiency in pediatric patients. Serono voluntarily discontinued U.S. sales in 2008 for commercial reasons rather than safety or efficacy concerns, which left sermorelin in an unusual regulatory position — a once-approved drug without an active NDA holder, now supplied primarily through compounding pharmacies.

Mechanism of Action

Sermorelin is a true GHRH agonist. It binds the GHRH receptor on anterior pituitary somatotrophs and triggers cAMP-mediated synthesis and pulsatile release of endogenous growth hormone. Because it acts upstream of the pituitary and preserves the negative-feedback loops governed by somatostatin and circulating IGF-1, GH output self-regulates in a way that exogenous recombinant human GH does not. In practice this means supraphysiologic GH spikes are harder to produce with sermorelin than with rhGH injection, which is one of the reasons its safety profile in children was relatively clean.

Sermorelin's pharmacokinetic weakness is a very short plasma half-life — roughly 11-12 minutes — because dipeptidyl peptidase-4 (DPP-4) rapidly cleaves the N-terminal Tyr-Ala bond. Longer-acting analogues such as CJC-1295 and Modified GRF (1-29) were designed specifically to address this limitation by adding DPP-4-resistant amino acid substitutions.

Clinical Evidence

Pediatric growth hormone deficiency is sermorelin's best-documented indication. Multicenter trials in the 1990s demonstrated increases in growth velocity roughly comparable to low-dose rhGH in children whose pituitary reserve was intact. Sermorelin also has a long history of use as a GH stimulation test — a pre-imaging diagnostic alternative to insulin-tolerance testing for suspected GHD.

Adult use is largely off-label. Small studies and clinical case series from anti-aging practice have examined:

• Adult-onset somatopause. Nighttime subcutaneous dosing has been reported to restore more youthful GH pulse amplitudes and modestly raise IGF-1 in older adults.
• Sleep architecture. Because endogenous GH release is tightly coupled to slow-wave sleep, sermorelin's physiologic mechanism tends to enhance rather than disrupt sleep quality.
• Body composition. Changes in lean mass and fat mass in adults have been reported but remain small compared with rhGH and are highly variable across individuals.

Practical Considerations

Typical adult research-use protocols are 200-500 mcg administered subcutaneously once daily at bedtime, on an empty stomach to avoid glucose-mediated blunting of GH release. Sermorelin is frequently paired with a GHRP such as ipamorelin because the two mechanisms synergize — GHRH analogues increase the amount of GH released per pulse, while GHRPs increase pulse frequency and amplitude through the ghrelin receptor. Our GHRH plus GHRP stacking explainer walks through the pharmacology of that combination in detail.

Safety and Regulatory Status

Reported side effects are generally mild — injection-site reactions, transient facial flushing shortly after dosing, occasional headache, and rare dysgeusia. Because sermorelin operates within physiologic feedback loops, the water retention, joint pain, and carpal tunnel symptoms that commonly complicate rhGH therapy are less frequent at standard doses.

Sermorelin is listed on the WADA prohibited list (class S2, Peptide Hormones) at all times. In the United States, it is not currently available as an FDA-approved drug product but has historically been compoundable under Section 503A, though that status has fluctuated with FDA bulk-substance guidance. It remains one of the oldest and best-characterized peptides in the growth-hormone category, with decades of clinical use behind it — a rare thing in this library.